PET-CT/MRI Department, Harbin Medical University, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province.
Scientific Research Center Department, Beijing General Electric Company, Beijing.
Nucl Med Commun. 2024 Dec 1;45(12):1069-1081. doi: 10.1097/MNM.0000000000001909. Epub 2024 Nov 5.
To establish nomograms for predicting preoperative lymph-vascular space invasion (LVSI) and survival outcomes of cervical squamous cell carcinoma (CSCC) based on PET/CT radiomics.
One hundred and twenty-three patients with CSCC and LVSI status were enrolled retrospectively. Independent predictors of LVSI were identified through clinicopathological factors and PET/CT metabolic parameters. We extracted 1316 features from PET and CT volume of interest, respectively. Additionally, four models (PET-RS: radiomic signature of PET only; CT-RS: radiomic signature of CT only; PET/CT-RS + clinical data; PET/CT-RS: radiomic signature of PET and CT) were established to predict LVSI status. Calculation of radiomics scores of PET/CT was executed for assessment of the survival outcomes, followed by development of nomograms with radiomics (NR) or without radiomics (NWR).
One hundred and twenty-three patients with pathologically confirmed CSCC had been categorized into two sets (training and testing sets). It was found that only maximum standardized uptake value (SUV max ) and squamous cell carcinoma antigen were independent predictors of LVSI. Meanwhile, the PET/CT-RS + clinical data outperformed the other three models in the training set [area under the curve (AUC): 0.91 vs. 0.861 vs. 0.81 vs. 0.814] and the testing set (AUC: 0.885 vs. 0.857 vs. 0.783 vs. 0.798). Additionally, SUV max and LVSI had been demonstrated to be independent prognostic indicators for progression-free survival and overall survival. Decision curve analysis and calibration curve indicated that NRs were superior to NWRs. The survival outcomes were assessed.
PET/CT-based radiomic signature nomogram enables a new method for preoperative prediction of LVSI and survival prognosis for patients with CSCC.
基于 PET/CT 放射组学建立预测宫颈鳞状细胞癌（CSCC）术前淋巴血管空间侵犯（LVSI）和生存结局的列线图。
回顾性纳入 123 例 CSCC 伴 LVSI 状态的患者。通过临床病理因素和 PET/CT 代谢参数确定 LVSI 的独立预测因素。分别从 PET 和 CT 感兴趣区提取 1316 个特征。此外，建立了 4 种模型（PET-RS：仅 PET 的放射组学特征；CT-RS：仅 CT 的放射组学特征；PET/CT-RS+临床数据；PET/CT-RS：PET 和 CT 的放射组学特征）来预测 LVSI 状态。计算 PET/CT 的放射组学评分，评估生存结局，然后分别建立有无放射组学（NR 和 NWR）的列线图。
123 例经病理证实的 CSCC 患者被分为两组（训练组和测试组）。结果发现，仅最大标准化摄取值（SUV max ）和鳞状细胞癌抗原是 LVSI 的独立预测因素。同时，在训练集（AUC：0.91 比 0.861 比 0.81 比 0.814）和测试集（AUC：0.885 比 0.857 比 0.783 比 0.798）中，PET/CT-RS+临床数据优于其他三种模型。此外，SUV max 和 LVSI 是无进展生存和总生存的独立预后指标。决策曲线分析和校准曲线表明，NR 优于 NWR。评估了生存结局。
基于 PET/CT 的放射组学特征列线图为预测 CSCC 患者 LVSI 和生存预后提供了一种新方法。
